Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amicus Therapeutics, a biopharmaceutical company developing orally-administered, novel small molecule drugs called pharmacological chaperones to treat rare diseases, has released additional positive data from the ongoing Phase 2 extension study of its investigational drug Amigal (migalastat HCl) indicated for the treatment of Fabry disease.
Subscribe to our email newsletter
Fabry’s disease is an inherited lysosomal storage disorder brought about by the deficiency of the alpha-galactosidase A (alpha-Gal A)enzyme.
The extension study designed to evaluate the long-term safety and efficacy of migalastat HCl showed that treatment with the drug was well tolerated with no drug-related serious adverse events, with the exception of the common headache, arthralgia, diarrhea and fatigue.
Amicus, in partnership with GlaxoSmithKline (GSK) is sponsoring an ongoing Phase 2 study to evaluate the co-administration of migalastat HCl with ERT for Fabry disease, the results of which are expected in the second half of 2011.
Amicus’ lead program is in Phase 3 for the treatment of Fabry disease.
Amicus Therapeutics also plans to present its preclinical study data evaluating the co-administration of pharmacological chaperones with enzyme replacement therapy (ERT) in Fabry disease, and in genetically defined subpopulations of Parkinson’s disease and Alzheimer’s disease.